Antibody MF-GFA-0060

for researchdiagnosticprotein

Quantifying GFAP in the sample easily, rapidly, and accurately Magnetic Nanoparticle Dextran layer For traumatic brain injury and Alzheimer’s disease research and for in-vitro diagnosis use Description Intended Use “MagQu” GFAP IMR Reagent is used to quantitatively measure glial fibrillary acidic protein(GFAP) in human fluid specimen, such as plasma, serum or CSF. Use “MagQu” GFAP IMR Reagent only with the XacPro-S System (MagQu Co., Ltd.). Introduction Glial fibrillary acidic protein (GFAP) is the main constituent of the astrocytic cytoskeleton, which plays an important role in the structure and mobility of astrocytes and can affect astrocyte function. The amount of GFAP in the blood begins to rise in the early stages of Alzheimer's disease. Symptoms of astroglial cell deposition can be a sign of the onset of early events in AD. Therefore, GFAP can be used to predict the future onset of Alzheimer's disease, mild cognitive impairment, and changes in the structural features of brain MRI in the elderly. 1,2 Principle of Test “MagQu” GFAP IMR Reagent is designed for rapid quantifying GFAP by ImmunoMagnetic Reduction (IMR). We conjugate antibody on the surface of around 50 nm-in-diameter Fe3O4 magnetic particles. When the antibodies on the surface bind with GFAP, the magnetic particles form clusters. Therefore, the ac susceptibility (Xac) of magnetic particles would be reduced in the adding ac magnetic field. By measuring the reduction of Xac, GFAP can be easily, rapidly and accurately quantified. Specification: Core Iron Oxide (Fe3O4) Layer Dextran Surface protein Anti-GFAP antibody Mean Diameter of Particles 50 ~ 60 nm